Biocon scores FDA approval for Pebrilzo, its fifth US cancer biosimilar
Biocon just landed FDA approval for Pebrilzo, a biosimilar to Perjeta, treating HER2-positive breast cancer. It's the company's fifth oncology biosimilar cleared in the U.S., though a Genentech settlement pushes the earliest licensed launch to Q3 2028.
- 14 sources report it: investywise.com, taxguru.in, scanx.trade, business-standard.com and 10 more.
- The source published it on Nov 15, 2026 at 4:00 PM.
Nothing open. Every check passed.
The U.S. Food and Drug Administration has cleared Biocon's Pebrilzo (pertuzumab-qcay) Injection, a biosimilar to Perjeta. It's the Indian drugmaker's fifth oncology biosimilar to win U.S. approval, and it slides straight into an already crowded cancer portfolio.
Pebrilzo is a monoclonal antibody aimed at HER2-positive breast cancer. It works by blocking HER2 receptors on cancer cells, which the company says puts a brake on aggressive tumor growth. Biocon has also locked in a global settlement and license agreement with Genentech, the maker of the reference product, setting the earliest licensed U.S. launch for the third quarter of calendar 2028.
The label covers metastatic breast cancer, where it's used alongside trastuzumab and docetaxel in patients who haven't had prior anti-HER2 therapy or chemotherapy for metastatic disease. It's also greenlit for early breast cancer, combined with trastuzumab and chemotherapy, both as neoadjuvant treatment for locally advanced, inflammatory or early-stage disease and as adjuvant treatment for HER2-positive early breast cancer at high risk of recurrence.
Regulators attached two warnings: Left Ventricular Dysfunction and Embryo-Fetal Toxicity. Patients are advised to get their cardiac function evaluated before and during treatment, and the drug is off-limits for anyone with a known hypersensitivity to pertuzumab or its excipients. The listed common side effects include diarrhea, alopecia, neutropenia, nausea, fatigue, rash and peripheral neuropathy, depending on the regimen.
Pebrilzo joins Ogivri, Jobevne, Fulphila and Aukelso on Biocon's U.S. oncology shelf. Behind them, the pipeline holds proposed biosimilars for trastuzumab/hyaluronidase, nivolumab and pembrolizumab, spanning HER2-directed therapy and immuno-oncology.
TopicsBiocon · FDA · Pebrilzo · Perjeta · Genentech · Ogivri · Jobevne · Fulphila
Written by AI from verified reporting.

